CR11106A - Inhibidores de cinasa p710 s6 - Google Patents

Inhibidores de cinasa p710 s6

Info

Publication number
CR11106A
CR11106A CR11106A CR11106A CR11106A CR 11106 A CR11106 A CR 11106A CR 11106 A CR11106 A CR 11106A CR 11106 A CR11106 A CR 11106A CR 11106 A CR11106 A CR 11106A
Authority
CR
Costa Rica
Prior art keywords
kinase inhibitors
formula
methods
relates
present
Prior art date
Application number
CR11106A
Other languages
English (en)
Spanish (es)
Inventor
Dean Dally Robert
Huang Jianping
Joseph Sajan
Alan Shepherd Timothy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR11106A publication Critical patent/CR11106A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR11106A 2007-05-11 2009-11-10 Inhibidores de cinasa p710 s6 CR11106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
CR11106A true CR11106A (es) 2010-04-12

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11106A CR11106A (es) 2007-05-11 2009-11-10 Inhibidores de cinasa p710 s6

Country Status (33)

Country Link
US (2) US8093383B2 (enExample)
EP (1) EP2148880B1 (enExample)
JP (1) JP5503532B2 (enExample)
KR (1) KR101088219B1 (enExample)
CN (1) CN101679439B (enExample)
AR (1) AR066344A1 (enExample)
AU (1) AU2008251692B2 (enExample)
BR (1) BRPI0811212A2 (enExample)
CA (1) CA2687265C (enExample)
CL (1) CL2008001230A1 (enExample)
CO (1) CO6241109A2 (enExample)
CR (1) CR11106A (enExample)
DK (1) DK2148880T3 (enExample)
DO (1) DOP2009000257A (enExample)
EA (1) EA016445B1 (enExample)
EC (1) ECSP099721A (enExample)
ES (1) ES2483726T3 (enExample)
GT (1) GT200900292A (enExample)
HR (1) HRP20140611T1 (enExample)
IL (1) IL201564A (enExample)
MA (1) MA31433B1 (enExample)
MX (1) MX2009012075A (enExample)
MY (1) MY154898A (enExample)
NZ (1) NZ580423A (enExample)
PE (1) PE20090887A1 (enExample)
PL (1) PL2148880T3 (enExample)
PT (1) PT2148880E (enExample)
RS (1) RS53451B (enExample)
SI (1) SI2148880T1 (enExample)
TN (1) TN2009000446A1 (enExample)
TW (1) TWI423805B (enExample)
UA (1) UA99284C2 (enExample)
WO (1) WO2008140947A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
CA2743242A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
MX2011005002A (es) * 2008-11-11 2011-05-25 Lilly Co Eli Inhibidor de p70 s6 quinasa y terapia de combinacion de inhibidor del receptor de egfr.
WO2010093419A1 (en) 2009-02-11 2010-08-19 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
BR112012002336A2 (pt) 2009-08-07 2016-05-31 Merck Patent Gmbh compostos aza-heterocíclicos
CA2778291C (en) * 2009-10-23 2014-02-11 Eli Lilly And Company Akt inhibitors
AR080643A1 (es) 2010-02-03 2012-04-25 Signal Pharm Llc Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
CA2803387C (en) 2010-07-29 2017-12-05 Bayard R. Huck Cyclic amine azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
CN103228649B (zh) 2010-11-24 2015-11-25 默克专利股份公司 喹唑啉甲酰胺氮杂环丁烷
PT2755965T (pt) * 2011-09-12 2017-11-02 Merck Patent Gmbh Novas imidazol aminas como moduladores da atividade quinase
JP6082011B2 (ja) 2011-09-12 2017-02-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ活性のモジュレーターとして使用するためのアミノピリミジン誘導体
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2890288A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
AU2013344549B2 (en) * 2012-11-16 2018-03-08 Xiaoling Chen Novel imidazol-piperidinyl derivatives as modulators of kinase activity
AU2013352261B2 (en) 2012-11-29 2018-05-10 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
US9458134B2 (en) * 2013-03-11 2016-10-04 Merck Patent Gmbh Heterocycles as modulators of kinase activity
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
EA030726B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
HK1221174A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
EP4218763A1 (en) 2013-04-17 2023-08-02 Signal Pharmaceuticals, LLC 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for treating glioblastoma multiforme
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
WO2015134536A1 (en) * 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3125935B1 (en) 2014-04-03 2019-10-23 Merck Patent GmbH Combinations of cancer therapeutics
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
MX2019015731A (es) 2017-06-22 2020-08-03 Celgene Corp Tratamiento de carcinoma hepatocelular caracterizado por infeccion por virus de hepatitis b.
JP2023551408A (ja) 2020-11-16 2023-12-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング がん処置のためのキナーゼインヒビター組み合わせ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US8076338B2 (en) * 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AU2005322085B2 (en) 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
JP5114395B2 (ja) 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
DOP2009000257A (es) 2010-03-31
EA200971051A1 (ru) 2010-06-30
HRP20140611T1 (hr) 2014-08-15
JP5503532B2 (ja) 2014-05-28
ECSP099721A (es) 2009-12-28
CA2687265A1 (en) 2008-11-20
PL2148880T3 (pl) 2014-10-31
EP2148880B1 (en) 2014-05-28
MA31433B1 (fr) 2010-06-01
EP2148880A1 (en) 2010-02-03
PT2148880E (pt) 2014-08-28
CO6241109A2 (es) 2011-01-20
CA2687265C (en) 2012-12-04
US20090163714A1 (en) 2009-06-25
BRPI0811212A2 (pt) 2014-10-29
HK1140767A1 (en) 2010-10-22
PE20090887A1 (es) 2009-07-13
GT200900292A (es) 2011-06-24
TWI423805B (zh) 2014-01-21
IL201564A0 (en) 2010-05-31
TN2009000446A1 (en) 2011-03-31
SI2148880T1 (sl) 2014-07-31
JP2010526814A (ja) 2010-08-05
ES2483726T3 (es) 2014-08-07
WO2008140947A1 (en) 2008-11-20
AU2008251692B2 (en) 2012-10-11
KR101088219B1 (ko) 2011-11-30
AR066344A1 (es) 2009-08-12
CN101679439A (zh) 2010-03-24
US8093383B2 (en) 2012-01-10
EA016445B1 (ru) 2012-05-30
DK2148880T3 (da) 2014-06-16
KR20100005710A (ko) 2010-01-15
RS53451B (sr) 2014-12-31
CN101679439B (zh) 2013-09-11
US20120071490A1 (en) 2012-03-22
IL201564A (en) 2014-08-31
MX2009012075A (es) 2009-11-19
AU2008251692A1 (en) 2008-11-20
CL2008001230A1 (es) 2009-05-22
NZ580423A (en) 2012-02-24
UA99284C2 (ru) 2012-08-10
TW200848053A (en) 2008-12-16
MY154898A (en) 2015-08-28

Similar Documents

Publication Publication Date Title
CR11106A (es) Inhibidores de cinasa p710 s6
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
CR11241A (es) Compuestos de pirazol y su uso como inhibidores de raf
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
DOP2010000387A (es) Compuestos pirazolicos 436
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
DOP2010000323A (es) Pirimidin-5-carboxamidas sustituidas 281
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CR10782A (es) Compuestos para inhibir la progresion mitotica
CR20110240A (es) Inhibidores de cinasa akt y p70 s6
ECSP077271A (es) Derivados de pirimidina
UY28745A1 (es) Nuevos compuestos
ECSP088296A (es) Compuestos terapéuticos
UY30460A1 (es) Compuestos terapéuticos
ECSP077259A (es) Derivados de pirimidina
CR9786A (es) Compuestos de bencimidazol-tiofeno
GT200800285A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
GT200600117A (es) Nuevos compuestos farmaceuticos
UY31000A1 (es) Oxoisoxazoles como inhibidores de lipasas y fosfolipasas
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.